Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
28 hedge funds and large institutions have $18.4M invested in Astria Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 10 closing their positions.
7% less funds holding
Funds holding: 30 → 28 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
21.57% less ownership
Funds ownership: 100.79% → 79.22% (-22%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
34% less capital invested
Capital invested by funds: $28.1M → $18.4M (-$9.66M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
+$232K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$109K |
| 3 |
BlackRock
New York
|
+$74.4K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$53.6K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$17.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.92M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.46M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$840K |
| 4 |
Millennium Management
New York
|
-$335K |
| 5 |
Renaissance Technologies
New York
|
-$285K |
ATXS Hedge Fund Activity: Q3 2018 in Review
28 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2018, worth a combined $18.4M — down 34% from $28.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATXS and 8 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Oppenheimer & Co, adding an estimated $232K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.92M sold.
- 28 institutional investors held Astria Therapeutics (ATXS) as of Q3 2018, down from 30 in Q2 2018.
- Funds reported $18.4M of Astria Therapeutics stock for Q3 2018, down 34% quarter-over-quarter.
- 8 funds opened new Astria Therapeutics positions in Q3 2018 and 10 closed out, a net change of -2 holders.
- The largest Astria Therapeutics buyer in Q3 2018 was Oppenheimer & Co, an estimated $232K added.
- The largest Astria Therapeutics seller in Q3 2018 was Armistice Capital, an estimated $1.92M sold.
Based on aggregated 13F filings for Q3 2018.